Overview
MP CARDIOFLOW-B (2160)
MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of str...
- Open
- 1.280
- High
- 1.280
- Low
- 1.280
- Prev. Close
- 1.280
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- 0.00%
- 52wk High
- 6.500
- Volume Ratio
- 0.00
- Turnover Ratio
- --
- 52wk Low
- 0.930
- HK Mkt Cap
- 1.63B
- Market CapHKD
- 1.63B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.115
- EPSDynamic
- -0.115
- EPSStatic
- --
- BVPS
- 1.57
- P/B
- 0.82
- HK Shares
- 1.27B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.27B
- Min lot size
- 1,000
- Currency
- HKD
MP CARDIOFLOW-B Analyst Rating
View moreForecast & Rating
Aug 8, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 2
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Aug, 31
MicroPort CardioFlow opened with a gap down and trended lower during the morning session, closing at HK$1.32, a 5.36% decline, primarily due to the company's announcement of delaying its board meeting and interim results release, fueling uncertainty over earnings. The company previously guided H1 2026 revenue of at least US$153 million but a net loss of up to US$25 million; Q4 2025 revenue grew 20.26% YoY to approximately HK$94.48 million, but net loss widened 2,455.28% YoY to about HK$72.0 million, with EPS of -HK$0.14 and ROE of -14.45%, underscoring persistent fundamental headwinds. Price-wise, the stock is down 68.57% from its 52-week high of HK$4.20 but still up 14.78% year-to-date, and trades above its 20-day (HK$1.28) and 60-day (HK$1.23) moving averages, suggesting some near-term recovery. While the appointment of Chen Guoming as CEO may signal a new strategic direction.
- Aug, 28
MicroPort CardioFlow opened lower and gradually declined, dropping from the morning start of HKD 1.48 to an intraday low of HKD 1.405 in the afternoon session, closing down 5.07%. The company announced a delay in the board meeting originally scheduled to review interim results and appointed Chen Guoming as the new CEO, drawing market attention to management stability. Financially, Q4 2025 revenue grew 20.26% YoY to HKD 94.5 million, but net loss widened to HKD 72 million, with EPS of -HKD 0.1389 deteriorating over 22 times YoY. The current price of HKD 1.405 sits 66.55% below the 52-week high of HKD 4.2, yet YTD gain of 22.17% and the price above the 20-day MA of HKD 1.27 suggest some resilience. Nonetheless, the company guided H1 2026 revenue of at least USD 153 million and a net loss of up to USD 25 million, implying a potential narrowing of losses compared to 2025.
- Aug, 27
MicroPort CardioFlow surged in the afternoon session, reaching HK$1.425 by 14:06 BJ, with intraday high of HK$1.435, up about 5.9% from Friday's close of HK$1.345, forming a V-shaped reversal after hitting a morning low of HK$1.33. The company earlier guided H1 2026 revenue of at least US$153 million but expects a net loss of up to US$25 million, while full-year 2025 loss widened to US$18.82 million, weighing on sentiment. The stock remains 66% below its 52-week high of HK$4.2 but has gained 23.9% YTD and sits above both MA20 (HK$1.253) and MA60 (HK$1.24), indicating short-term momentum. However, the widening loss, CEO change, and delayed board meeting for interim results inject uncertainty.
- Aug, 24
MicroPort CardioFlow opened at HK$1.38 in the morning session but slid to HK$1.31 by 10:36 BJ, down 5.07%, with a thin 0.03% turnover rate and 325,000 shares traded. The decline was driven by the company's H1 2026 revenue outlook of at least US$153 million but a net loss of up to US$25 million, alongside a full-year 2025 loss widening to US$18.82 million and a Q4 net profit margin of -76%, with net profit shrinking 2,455% YoY. The stock is now 68.81% below its 52-week high of HK$4.2, though still up 13.91% YTD, and hovers near its MA20 (HK$1.214) and MA60 (HK$1.255), risking a break below moving averages. However, the initiation of the STARLIGHT trial for the LINEA pacing lead offers a potential long-term catalyst.
- Aug, 20
MicroPort CardioFlow (2160.HK) staged a low-to-high rebound in the morning session, rising from HK$1.27 to HK$1.37, a gain of approximately 7.9%, driven by the company's preliminary H1 2026 revenue guidance of at least US$153 million and a net loss cap of US$25 million, which marked a narrower loss trajectory compared with the prior year's persistent expansion, along with positive clinical progress from the STARLIGHT trial for left bundle branch pacing leads. The current price of HK$1.37 remains 67.38% below the 52-week high of HK$4.2, yet it has gained 19.13% year-to-date and now trades above both the 20-day moving average (HK$1.191) and the 60-day moving average (HK$1.267), indicating improving short-term momentum. However, the latest quarterly net loss widened more than 20-fold year-over-year to HK$0.1389 per share, underscoring ongoing fundamental weakness.
News
Global Report · Consolidation and Volatility: How Hong Kong's Niche Market Leaders Are Rewriting Their Narratives
Global Report · A Device Approval, a Frozen Stock: MicroPort NeuroTech's Long Halt
Global Report · Venus Medtech's state rescue: China's valve makers bet on exports
Weekly Review · Weekly Recap | MP CARDIOFLOW-B this week, halted with no catalysts
Weekly Review · Weekly Recap | MP CARDIOFLOW-B this week, halted throughout
CoinLive · Suspended Hong Kong-Listed Companies List Updated
